Chitinase‐3‐Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers
Brain and Behavior · 2025-06 · 15 (6)
DOI: 10.1002/brb3.70619 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Brain and Behavior, online erschienen am 10.06.2025. Verfasst von R Novobilský und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Chitinase-3-Like Protein 1, Cognitive Dysfunction, Movement Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Introduction
Chitinase‐3‐like protein 1 (CHI3L1) is a glycoprotein implicated in various neurological conditions. It is associated with neuroinflammation and tissue remodeling. The study aimed to validate the reference interval (RI) of serum (S) CHI3L1 in a control group, to correlate S CHI3L1 values with other biomarkers of neurodegenerative damage, and to estimate the diagnostic accuracy of S CHI3L1.
Methods
Samples from 108 healthy volunteers were used to estimate the S CHI3L1 RI. For the comparison, we used cerebrospinal fluid (CSF) and serum (S) samples from 121 patients with cognitive disorders, and cognitive deterioration was assessed using the Mini‐Mental State Examination (MMSE). ELISA assays were used to determine the S CHI3L1, CSF, and S neurofilament light chain (NfL) levels; CSF and plasma β‐amyloid peptide 42 ; CSF and plasma β‐amyloid peptide 40 ; CSF total tau protein; CSF phosphorylated tau protein; and CSF alpha‐synuclein.
Results
The estimated RI of S CHI3L1 was 14.44 to 63.11 µg/L. The cut‐off value of S CHI3L1 was 34.37 µg/L. ROC analysis showed that S CHI3L1 has 81.4% sensitivity and 76.9% specificity. We found a moderate Spearman's rank correlation coefficient between the S CHI3L1 and age ( r S = 0.486; p < 0.001) and between S CHI3L1 and S NfL ( r S = 0.489; p < 0.001) in all groups. The Kruskal–Wallis test showed a significant overall difference in S CHI3L1 among diagnostic groups ( p = 0.013). S CHI3L1 and CSF NfL had statistically significant effects on MMSE values (multiple R 2 was 0.431).
Conclusions
Our results suggest that S CHI3L1 reflects the severity of cognitive deficits assessed by MMSE. It can be used as a supportive biomarker in neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic.
- Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czech Republic.
- Institute of Laboratory Medicine, Department of Clinical Biochemistry, University Hospital Ostrava, Ostrava, Czech Republic.
- Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czech Republic.
- Faculty of Electrical Engineering and Computer Science, Department of Applied Mathematics, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
- Department of the Deputy Director for Science, Research, and Education, University Hospital Ostrava, Ostrava, Czech Republic.
ORCID-Profile: R Novobilský
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Novobilský, R., Bártová, P., Stejskal, D., Kondé, A., Bar, M., & Kušnierová, P. (2025). Chitinase‐3‐Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers. Brain and Behavior, 15(6). https://doi.org/10.1002/brb3.70619
Vancouver
Novobilský R, Bártová P, Stejskal D, Kondé A, Bar M, Kušnierová P. Chitinase‐3‐Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers. Brain and Behavior. 2025;15(6). doi:10.1002/brb3.70619
BibTeX
@article{Novobilsk2025,
author = {Novobilský, R and Bártová, P and Stejskal, D and Kondé, A and Bar, M and Kušnierová, P},
title = {Chitinase‐3‐Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers},
journal = {Brain and Behavior},
year = {2025},
volume = {15},
number = {6},
doi = {10.1002/brb3.70619}
}
EUVIMED